Projects

RADAR-CNS

Wearable devices that help prevent and treat depression, multiple sclerosis and epilepsy

The RADAR-CNS project aims to develop new ways of monitoring major depressive disorder, epilepsy, and multiple sclerosis using wearable devices and smartphone technology. Such widely available devices can reveal a patient’s current condition, remotely, at previously unachievable levels of detail. A project consortium of 24 includes commercial and academic partners from across Europe and the US.

icon_Money € 25 M


funding from IMI, EFPIA

icon_world 22


partners in Europe and the US

About RADAR-CNS

RADAR-CNS* is jointly led by King’s College London and Janssen Pharmaceutica NV, with funding from the Innovative Medicines Initiative (IMI) and contributions in-kind from commercial partners. Its goal is to predict and pre-empt relapses in patients with major depressive disorders, epilepsy, and multiple sclerosis, and to improve their quality of life. The consortium brings together experts from diverse fields including clinical research, engineering, computer science, information technology, data analytics and health services. Both patients and health care providers will be involved.
*RADAR-CNS: Remote Assessment of Disease and Relapse – Central Nervous System

Managing of a multi-disciplinary program, combined with data analysis and regulatory expertise

Lygature, is a member of the Management Team. In addition, together with linked partner The Hyve, Lygature is leveraging expertise developed during its Translational Research IT (TraIT) project to address the data analysis challenge. It is also looking at regulatory issues and ways in which such devices can be qualified.

  • Coordination and communication. Lygature is co-lead of the Project Management work package in RADAR-CNS and coordinates this large and multi-disciplinary program on a day-to-day basis. Activities include monitoring the effective execution of the work plan and its progress, creation and alignment of work processes, resource management and internal communication. In addition, Lygature provides the backbone for knowledge sharing and is responsible for the design and development of the public website.
     
  • Data analysis. RADAR-CNS requires ground-breaking work to isolate successfully normal biosignatures, as recorded by wearable devices. Patients are being followed from doctors’ perspectives, for correlation with device data. Lygature is using its data management expertise to integrate data from various sources, relating werables-derived data to disease symptoms and allowing scientists to assess if measured changes are predictive.
     
  • Regulatory requirements. The project is also exploring new territory around regulation, posing important questions concerning the use of everyday devices for medical monitoring. Lygature will be looking at how such devices will be deployed, what requirements need to be met and how they can be qualified across different jurisdictions for this application.

The contribution made by Lygature to RADAR-CNS is an example of how cross-disciplinary expertise built up during major projects can be applied in new areas. An ability to extract meaningful data from complex data sets has been proven during the TraIT project, and the Lygature team offers, through its Escher platform, all of the experience needed to overcome diverse regulatory hurdles.

Lygature together with

Project updates


  • RADAR-CNS researchers: Interview series “Behind-the-scenes”

    In order to showcase the work we do in RADAR-CNS, we dedicate the following news stories to our researchers. They share with us what work they do on the project, what they like and what challenges them about this work and how they have adapted to the new circumstances created by the COVID-19 pandemic.

    Read all interviews here.

  • people sitting in circle with cogwheels

    Consultation meeting at EMA: Joint effort of the RADAR-CNS and RADAR-AD consortium members

    On the 4th of February 2020, RADAR-CNS and RADAR-AD project members visited the European Medicines Agency (EMA) in Amsterdam, The Netherlands for a consultation meeting with the Innovation Task Force (ITF). The objective of EMA’s ITF briefing meetings is to set the stage for scientific and regulatory discussions that relate to the development of new medicinal products and technologies. The purpose of this meeting was to inform the IMI on the both RADAR projects, and to exchange thoughts on a number of items that are associated with remote measuring technologies and the development of digital endpoints.

    Read more.

  • RADAR-CNS team gathers in Athens to share ideas and explore challenges

    Nearly 80 members of the RADAR-CNS team met in May in Athens, Greece for three days of problem solving, sharing of ideas and assessing progress on outcomes. The RADAR-CNS Annual Meeting is an opportunity for people working on the full range of work streams to come together to explain and explore challenges and solutions, as well as to investigate new applications of the technology and plan ahead for its translation to real life settings. 

    Read More